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Abstract 1 
 High-dose opioid administration is associated with significant adverse events. 2 
Evidence suggests that low-dose ketamine infusions improve perioperative analgesia over 3 
conventional opioid management, but usage is highly variable. Ketamine’s adverse drug 4 
effects (ADEs) are well known, but their prevalence during low-dose infusions in a 5 
clinical setting and how often they lead to infusion discontinuation are unknown. The 6 
purposes of this study were threefold: 1) to identify patient factors associated with 7 
initiation of ketamine infusions during spine surgery; 2) to identify specific spine 8 
procedures in which ketamine has been used most frequently; and 3) to identify ADEs 9 
associated with postoperative ketamine infusions and which ADEs most frequently led to 10 
discontinuation. Spine surgery was chosen because of its association with moderate to 11 
severe pain and a relatively high use of ketamine infusions in this population at our 12 
hospital.13 
 4 
Introduction 1 
 Patients presenting for surgery due to conditions associated with chronic pain 2 
frequently are being treated with opioids, often at alarmingly high doses. One study of 3 
Medicaid enrollees found that 63.5% of patients with non-cancer chronic pain had taken 4 
an opioid in the prior 12 months, an increase of 18.9% from five years prior.1 Yet despite 5 
escalating doses of opioids, patients continue to report that their chronic pain is not well 6 
controlled.2 At the same time, serious adverse drug effects (ADEs) associated with 7 
opioids, including fatal respiratory depression, continue to be a serious concern.3 In 8 
patients chronically taking opioids, tolerance to respiratory depression is incomplete4 and 9 
such patients have an increased risk of overdose and death compared to non-opioid 10 
users.5 Analgesic alternatives to opioids are, therefore, highly desirable. 11 
 One such alternative during the perioperative period is ketamine, an 12 
N-methyl-D-aspartate (NMDA) receptor antagonist. A role of the NMDA receptor in the 13 
development of opioid tolerance was suggested by studies from several decades ago.6,7 14 
Ketamine is a potent analgesic that does not cause respiratory depression, and may 15 
improve postoperative analgesia while reducing opioid consumption.8,9 As an additional 16 
potential benefit, recent evidence suggests that intravenous (IV) ketamine may decrease 17 
the incidence of persistent postsurgical pain (PPSP).10 Ketamine infusions at our 18 
institution have been used both intraoperatively by the anesthesia team and 19 
postoperatively by the acute pain management service (APMS) as part of an 20 
opioid-sparing strategy in complex, opioid-tolerant patients. 21 
 We had three primary objectives of the current study: 1) to identify factors 22 
associated with current decisions by anesthesiologists to initiate ketamine during spine 23 
 5 
surgery; 2) to identify specific spine procedures in which ketamine has been used most 1 
frequently; and 3) to identify ADEs associated with all postoperative ketamine infusions 2 
and which ADEs most frequently led to discontinuation. This information is necessary 3 
for us to design prospective, randomized clinical trials comparing IV ketamine to placebo 4 
in opioid-tolerant patients. Spine surgery was chosen to study in detail because it is 5 
typically associated with moderate to severe postoperative pain, over 50% of our 6 
ketamine use has been in spine surgery, and this is a high-volume service at our 7 
institution. We retrospectively analyzed the preoperative medications and surgical details 8 
of all patients over a three-year period who underwent any type of elective spine surgery 9 
and also examined a sample of postoperative patients from all surgical specialties who 10 
received ketamine infusions for the presence of ADEs and classified them. 11 
  12 
 6 
Methods 1 
 2 
 This study was approved by the Thomas Jefferson University institutional review 3 
board without requirement for written patient consent. 4 
 All patients admitted on the day of surgery following elective spine surgery by an 5 
orthopedic surgeon or neurosurgeon under general anesthesia between January 1, 2012 6 
and March 21, 2015 at Thomas Jefferson University Hospital (TJUH) were studied. 7 
TJUH is a major academic medical center, as well as a regional spinal cord trauma center 8 
with a high spine surgery volume. Patients undergoing microdiscectomy at our hospital 9 
are usually cared for on an outpatient basis, and therefore most of those patients were not 10 
included, since their post-operative data were not available. Demographic data, 11 
preoperative medications, and dose and timing data related to ketamine infusions were 12 
retrieved from the hospital’s anesthesia information management system (Innovian®, 13 
Dräger, Telford, PA) and from the pharmacy information system database (Pyxis®, 14 
CareFusion, San Diego, CA). Patients who received intraoperative ketamine boluses but 15 
not an infusion were excluded. Data elements analyzed included the date of surgery, age 16 
in years, gender, weight, body mass index, American Society of Anesthesiologists (ASA) 17 
physical status, scheduled duration of surgery, primary surgical service, and preoperative 18 
medications. Preoperative opioids were classified as being taken on a “scheduled” or “as 19 
needed” basis (Table 2). Planned procedures (using locally defined, procedure-specific 20 
codes) were queried from the operating room case scheduling system (ORSOS®, 21 
McKesson, San Francisco, CA). All planned, elective spine surgeries requiring hospital 22 
admission (but not emergencies or cases booked as “add-ons”) were included for 23 
analysis. The decision to start an intraoperative ketamine infusion at our hospital was 24 
 7 
made by the attending anesthesiologist for the case. Data retrieved from the pharmacy 1 
information system were aligned with patient anesthesia records to determine if 2 
postoperative ketamine infusions had been started intraoperatively or initiated after the 3 
patient left the OR.  4 
 ADE data were retrieved from the daily notes recorded contemporaneously by the 5 
Acute Pain Management Service (APMS) nurses on a consecutive sample of 321 patients 6 
who received a postoperative ketamine infusion while on the APMS from January 1, 7 
2011 through December 31, 2013. Patients from all surgical subspecialties were included 8 
for the ADE analysis, not just those undergoing spine procedures. All APMS nurses had 9 
undergone training on the management of ketamine infusions, including the recognition 10 
of side effects. No special monitoring, such as telemetry or intensive care, has been 11 
required at our institution for patients receiving ketamine. Criteria for discontinuation of 12 
ketamine infusions included the patient requesting discontinuation due to ADEs or the 13 
patient’s primary service requesting discontinuation. 14 
 Data were extracted and prepared for analysis using SQL Server 2008 R2 15 
(Microsoft, Redmond, WA). Odds ratios (OR) were computed using the function 16 
oddsRatio in the R mosaic library, Pearson’s chi-square test (with Yate’s continuity 17 
correction), two-group Student t tests (with the Satterthwaite approximation), and local 18 
polynomial regression fits using the functions chisq.test, t.test, and loess, respectively, in 19 
the R stats library (R v3.2.0, The R Foundation for Statistical Computing, Vienna, 20 
Austria).  21 
  22 
 23 
 8 
Results 1 
Demographics and Preoperative Medications Associated with Ketamine Administration 2 
 There were 4958 patients who underwent elective spine surgery under general 3 
anesthesia during the study interval, 4748 of which were entered into our electronic 4 
preoperative anesthesia system and had data available for analysis, and 211 of whom 5 
received an intraoperative infusion of ketamine. Among all patients, those receiving 6 
ketamine were younger (difference = -4.4 years, 95% CI -2.2 to -6.0 years, P <10-6), had 7 
a higher ASA Physical Status (P <10-6), and were scheduled for surgeries of longer 8 
estimated duration (difference = 72 minutes, 95% CI 60 to 84 minutes, P <10-6),  (Table 9 
1). There were no significant differences in weight or BMI between the two groups. 10 
Males and females were represented equally (difference = -0.40%, 95% CI -3.1% to 11 
2.3%, P = 0.77). 12 
 Medication factors at the time of the preoperative evaluation associated with a 13 
greater likelihood of receiving an intraoperative ketamine infusion were taking vs. not 14 
taking a scheduled opioid (OR 16.09, 95% CI 11.98 to 21.59), taking any opioid vs. no 15 
opioid (OR 10.25, 95% CI 7.13 to 14.75), and taking vs. not taking an anti-depressant 16 
(OR 2.69, 95% CI 2.02 to 3.57) (Table 2). Patients who were taking both a scheduled 17 
opioid and an anti-depressant were more likely to receive ketamine than those taking just 18 
a scheduled opioid (OR 1.64, 95% CI 1.11 to 2.46; Table 2).  19 
Among the 552 patients who were taking a scheduled opioid at the time of the 20 
preoperative evaluation, those receiving a ketamine infusion were younger (difference 21 
= -2.8 years, 95% CI -0.6 to -5.1 years, P = 0.012), had a higher ASA Physical Status (P 22 
= 0.01), and were scheduled for surgeries of longer estimated duration (difference = 49 23 
 9 
minutes, 95% CI 32 to 67 minutes, P <10-6),  (Table 3). There were no significant 1 
differences in weight or BMI between the two groups. There was a higher proportion of 2 
females (difference = 13.3%, 95% CI 4.3 to 22.3%, P = 0.005). 3 
 4 
Surgical Procedures Associated with Ketamine Administration 5 
 There were 20 distinct spine procedures (12 primary spine procedures and 8 6 
revision spine procedures) identified in the database (Table 4). Of these, there were 10 7 
procedures that had  5% prevalence of intraoperative ketamine administration. The three 8 
most commonly performed of these 10 were posterior thoracic/lumbar fusion (N = 148 9 
cases), anterior thoracic/lumbar fusion (N = 136 cases), and anterior/posterior cervical 10 
fusion (N = 137 cases). Specific spine procedures are displayed in Table 4 according to 11 
primary or revision status. 12 
 13 
Side Effects of Low-Dose Ketamine Infusions 14 
 There were 31.8% of patients who experienced at least one ADE (Table 5). The 15 
most frequent ADE was CNS excitation (16.2%), followed by sedation (9.4%) and visual 16 
disturbances (3.1%). Some patients experienced more than one ADE (Table 5). Thirty-17 
seven patients (36.3% of all patients with an ADE) experienced ADEs severe enough to 18 
have resulted in discontinuation of the ketamine infusion. The reasons for infusion 19 
discontinuation are described in Table 5. Sedation was the ADE most likely to result in 20 
ketamine discontinuation. Of the 37 patients whose infusions were discontinued, 35 of 21 
them reported resolution of symptoms after the infusion was stopped. Twenty-six patients 22 
received benzodiazepines, commonly used for treatment of side effects at our hospital, 23 
 10 
while 11 patients did not. To view the TJUH ketamine infusion guidelines, see Appendix 1 
A.  2 
 A postoperative infusion rate above 20 mg/hr was not associated with an 3 
increased chance of having the infusion stopped compared to patients receiving ≤ 20 4 
mg/hr (OR 0.71, 95% CI 0.34 to 1.5). The chance of discontinuation was also not 5 
increased with a threshold of 10 mg/hr (OR 0.69, 95% CI 0.32 to 1.5).  6 
  7 
 11 
Discussion 1 
 In this observational study, we found that patients who received intraoperative 2 
ketamine infusions tended to be younger, sicker, and undergoing spine procedures of 3 
longer duration (i.e., more complex) than those who did not. Patients who received 4 
ketamine infusions were more likely to be taking preoperative opioids, and this increased 5 
if patients were taking opioids on a scheduled basis.  6 
 We found that patients who were most likely to receive ketamine were those 7 
undergoing the most complex spine procedures, often involving both an anterior and 8 
posterior component or a revision procedure (Table 4). Previous studies examining 9 
ketamine in spine surgery have yielded conflicting results regarding postoperative opioid 10 
consumption.8,11-13 The lack of consistent findings may have resulted, in part, from 11 
combining potentially different procedures, listed as “lumbar fusion,”8 “lumbar or 12 
thoracolumbar laminectomy and fusion,”12 or “elective spine surgery.”13 Our data, 13 
however, suggest that anesthesiologists viewed patients undergoing longer, complex 14 
procedures differently than less complex cases. For example, one of the most common 15 
procedures, primary posterior lumbar fusion, had a low prevalence of ketamine 16 
administration, suggesting that providers believed conventional opioid analgesia was 17 
adequate. Patients who may benefit most from ketamine should be targeted for future 18 
studies examining important long-term outcomes of interest. Those patients undergoing 19 
presumably less painful procedures with lower incidence of persistent postsurgical pain, 20 
such as primary posterior lumbar fusion or anterior cervical fusion, may be able to be 21 
managed with conventional therapy. Consistent with previous studies,9 the more complex 22 
 12 
and painful spine procedures were the ones most likely to be associated with ketamine 1 
administration as a continuous infusion. 2 
 The apparent increased prevalence of ketamine use in patients taking both anti-3 
depressants and scheduled opioids was not surprising as the link between chronic pain, 4 
anti-depressants, opioids, and spine surgery has been described.14 Although it is 5 
impossible to determine retrospectively if this combined therapy factored into the 6 
decision-making process by the anesthesia team, anti-depressant use is a potential 7 
confounder that should be controlled for in future studies comparing ketamine to other 8 
therapies. 9 
 Our results also confirm the tolerability of ketamine’s ADEs in a clinical setting 10 
(Table 5). This agrees with clinical trials in which up to 0.25 mg/kg/hr have been tried 11 
without major ADEs.13 Our observed prevalence of central nervous system ADEs 12 
(16.2%) is similar to the 22% retrospectively described by Rasmussen.15 Thus, 13 
consideration of a variable-rate postoperative ketamine infusion in a treatment arm of a 14 
randomized clinical trial is reasonable. Our ADE data confirm those from Mayo Clinic, 15 
Jacksonville16 but go a step further in describing the specific ADEs, their prevalence, and 16 
the rate of discontinuation in a daily clinical practice in which the infusion rates are 17 
adjusted frequently.  18 
 Discontinuation of ketamine due to ADEs was unrelated to the maximum dose, a 19 
somewhat surprising finding. Several factors may have played a role in this, including 20 
ADEs resulting from simultaneous administration of opioids and benzodiazepines, as 21 
well as variable patient sensitivity to ketamine, some of which may be related to 22 
individual changes at the cellular level.17 There may be other unidentified factors as well. 23 
 13 
Because 35 out of the 37 patients had resolution of symptoms once the infusions were 1 
stopped, this suggests that the side effects were at least partially due to ketamine.  2 
 Using the data from this observational study, we are currently designing a 3 
prospective, randomized trial comparing intra- and postoperative ketamine infusions to 4 
placebo in opioid-tolerant patients undergoing complex spine surgery with particular 5 
focus on long-term outcomes. Only complex spine procedures that  are more likely to 6 
result in severe pain will be included (i.e. anterior/posterior  procedures or procedures 7 
involving two or more spine areas, such as thoracic and lumbar). We will use the 8 
frequency of ADEs encountered to guide the process of obtaining informed consent. The 9 
ADE data could also be used as a guide for any hospitals considering starting a ketamine 10 
service on the general medical floors. 11 
 Our study may have limited generalizability in that the decision to start an 12 
intraoperative ketamine infusion was made at the discretion of the attending 13 
anesthesiologist for the case. Thus, our findings may not apply to all practices. Second, 14 
some patients may have been inappropriately placed in the “scheduled” opioid group 15 
rather than the “as needed” group or vice versa due to documentation issues or patients 16 
misrepresenting their opioid use. 17 
 In conclusion, we confirmed that postoperative ketamine infusions may be given 18 
safely on general medical floors without special monitoring or intensive care, and 19 
intraoperative infusions tend to be started for patients taking opioids, especially 20 
scheduled opioids. Our data provide guidance both for hospitals considering the use of 21 
ketamine infusions and for the design of future prospective, randomized clinical trials 22 
looking at long-term benefits of ketamine or its ADEs. 23 
 14 
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